BrainScope

ADDF & BrainScope: A Powerful Partnership Against Alzheimer’s

About this Event

Early Alzheimer’s diagnosis is crucial for accessing timely treatments, planning for the future, maximizing quality of life, and reducing patient anxiety. It allows individuals to make informed decisions and retain independence longer.

One of the best tools for early Alzheimer’s detection is EEG. BrainScope recently completed a successful proof-of-concept phase for a novel brain activity-based biomarker for the prediction of onset of Alzheimer’s disease at its earliest stage in normal elderly individuals with memory complaints. This breakthrough was supported by an investment from the Alzheimer’s Drug Discovery Foundation (ADDF).

BrainScope’s platform combines traditional EEG with AI, enhancing accuracy for early, non-invasive diagnosis, even before structural damage is visible, helping track disease progression and treatment effectiveness.

Please watch our Fireside Chat with Karen Harris, CFO & Head of Mission Related Investments for ADDF, Matt Adams, CEO of BrainScope, and Leslie Prichep, BrainScope’s Chief Science Officer, discover BrainScope’s potential to transform how Alzheimer’s is diagnosed and treated.

Video On Demand

– Recorded

January 8

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.